Dhaliwal Harpreet S. reported option exercise involving 17,000 shares of Vaxcyte, Inc. at $24.79 for $421k on Nov 11, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Technical Ops Officer
Chief Technical Ops Officer
Filed Nov 13, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$421,430Shares × reported price
Shares traded
17,000Common Stock
Price per share
$24.79Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
85,085Direct
Trade date
Nov 11, 2026Option exercise
Filed
Nov 13, 2026, 4:09 PM ET2-day reporting delay
Accession
0001886794-26-000014Code M · Transaction 400553
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 11, 2026Option exercise17,000$0.00$0Trade 400557
Nov 11, 2026Sell7,135$67.33−$480,399.55Trade 400554
Nov 11, 2026Sell9,345$68.16−$636,917.82Trade 400555
Nov 11, 2026Sell520$68.82−$35,785.88Trade 400556
5 transaction rows in this filing. Joint filers share the same rows.

PCVX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
PCVX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 20, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago +9.2%1w ago +1.5%1d ago +2.6%
Returns since7d30d90d180d1y

Footnotes in full

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on April 6, 2026. F2: The price reported is a weighted-average price. The shares were sold at prices ranging from $66.76 to $67.755. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $67.76 to $68.75. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F4: The price reported is a weighted-average price. The shares were sold at prices ranging from $68.76 to $68.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. F5: No other shares of common stock subject to the restrictions on transfer set forth in a Lock-Up Agreement dated October 6, 2026 were sold by the Reporting Person. F6: Stock Option is fully vested and exercisable.